ClinicalTrials.gg
CompletedNCT01401127Updated Nov 8, 2011

Managing Insulin Pumps for Exercise - Study 1

An observational study in Type 1 Diabetes Mellitus, sponsored by Buckinghamshire Healthcare NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-08.

Sponsored by Buckinghamshire Healthcare NHS Trust · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
16
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 41 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.

Planned enrollment
50th of 54
16 · median 133
Started
2011
with 10 others
Observational
54 of 268
14 open now
Registered
57th of 268
by date

Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 50th largest by planned enrollment of the 54 observational ones that give a count, is one of 11 that started in 2011, is one of 54 observational ones, and was the 57th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, or all of them as a file.
02

Study summary

People with Type 1 Diabetes Mellitus (T1DM) like to take part in sport and exercise, but problems with metabolism and blood glucose control can make this difficult. Some people with T1DM administer their insulin via an insulin pump, also know as continuous subcutaneous insulin infusion (CSII) therapy, in which a background or basal level of insulin is constantly infused under the skin by a special pump, with bolus doses of insulin given to accompany food. Clinical experience suggests that this may be particularly useful for managing diabetes for exercise, but there is limited experimental evidence to support this. The aim of this research , which is divided into three parts, is to investigate the hypothesis that the physiological response to sub-maximal (moderate) exercise of a person with type 1 diabetes treated with CSII, can be made to approximate more closely to the physiological response of a healthy individual by a prior reduction of their basal insulin infusion rate. This first part of the research is designed to compare metabolic response to exercise between people without diabetes and people with T1DM running there insulin pump at the usual basal rate.

Read the detailed description

For the first part of the study, participants will be either people with type 1 diabetes treated with insulin pump therapy or volunteers without diabetes. The 2 groups will be matched as far as possible by age, body mass index and usual level of activity. Participants will attend an exercise laboratory on 2 occasions. On the first occasion, which can take place at any time of day, formal written consent will be obtained for participation in the study. Participants will then undergo measurement of maximal exercise capacity (VO2 MAX). On the second occasion they will attend 2 hours after a lunch containing 60 grams of carbohydrate (advice will be given on how this can be achieved). A cannula will be inserted on arrival and blood samples obtained. Arterialised samples will be obtained by using a heated hand technique. Once the cannula has been inserted participants with type 1 diabetes will be asked to reduce the basal insulin infusion rate on their insulin pump to 70% of normal until the end of the study visit. After 30 minutes a further set of blood samples will be obtained, and participants will then start to exercise for 1 hour at 50% VO2 MAX. A further set of blood samples will be obtained at the end of the hour of exercise. Participants will then rest for 30 minutes before a final set of blood samples is taken. At this point the cannula will be removed and the study visit ends. Participants with diabetes will be given the choice to return basal insulin infusion rate to normal at this point. A snack will be offered.

Blood glucose will be monitored every 10 minutes and also if a participant feels symptoms of hypoglycaemia. If hypoglycaemia occurs the protocol will be stopped and carbohydrate given until the blood glucose level returns to the normal range.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Type 1 Diabetes Mellitus
  • Exercise
  • Continuous Subcutaneous Insulin Infusion
  • CSII
  • Insulin Pump Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with Type 1 Diabetes treated with insulin pump therapy who exercise for at least 1 hour each week and comparable participants without diabetes mellitus

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For participants with Type 1 Diabetes Mellitus

  • Participant is willing and able to give for participation in the study.
  • Male or Female, aged between 18 and 65 years
  • Diagnosed with Type 1 diabetes mellitus
  • Treated with CSII for at least 3 months
  • Exercises regularly for more than 1 hour per week

For participants without Type 1 Diabetes Mellitus

  • Participant is willing and able to give informed consent for participation in the study
  • Male or female, aged between 18 and 65 years
  • Exercises regularly for more than 1 hour per week

Exclusion criteria

Exclusion Criteria:

For participants with type 1 Diabetes Mellitus

  • People with any one of the following complications of diabetes:

    1. stage 2+ diabetic retinopathy
    2. renal impairment (with creatinine >150micromol/l)
    3. known history or symptoms of cardiovascular disease
    4. foot ulceration
    5. peripheral vascular disease
  • Known pregnancy or breastfeeding
  • Untreated or unstable respiratory disease
  • Known hypoglycaemia unawareness
  • Treatment with drugs known to interfere with glucose metabolism

For participants without Type 1 Diabetes Mellitus

  • Known pregnancy or breastfeeding
  • Untreated or unstable respiratory disease
  • Diagnosis of impaired fasting glucose, impaired glucose tolerance or diabetes mellitus
  • Treatment with drugs known to interfere with glucose metabolism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
16 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Type 1 Diabetes

    Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate

  • Participants without diabetes

    Participants without diabetes or evidence of impaired glucose regulation

06

What researchers measure

Primary outcomes

  1. Glucose excursion

    The primary outcome measure is change in blood glucose (glucose excursion) between the start and the end of exercise

    Time frame: Glucose will be measured at the start and end of 1 hour of exercise at 50% VO2 MAX during the second study visit

Secondary outcomes

  1. Comparison between the two groups of levels of lactate

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  2. Multiple correlation between blood glucose values and values of lactate, NEFA, betahydroxybutyrate, catecholamines, glucagon, insulin, C-peptide, human growth hormone and cortisol

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  3. Ratio of respiratory quotient (RQ) at the beginning of exercise to RQ at the end of exercise, compared between the two groups, which will give information about fuel use during exercise.

    Time frame: Respiratory quotient will be calculated using a breath by breath analyser using 2 minutes of data from the start at the end of exercise

  4. Comparison between the two groups of levels of non-esterified fatty acids (NEFA)

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  5. Comparison between the two groups of levels of beta-hydroxybutyrate

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  6. Comparison between the two groups of levels of circulating catecholamines

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  7. Comparison between the two groups of levels of glucagon

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  8. Comparison between the two groups of levels of circulating insulin

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  9. Comparison between the two groups of levels of human growth hormone

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

  10. Comparison between the two groups of levels of cortisol

    Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)

07

Study locations

1 site
  • Wycombe Hospital
    High Wycombe, Buckinghamshire HP11 2TT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2011
First posted
Jul 25, 2011
Start
Jan 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Last update
Nov 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01401127
Lead sponsor
Buckinghamshire Healthcare NHS Trust
Collaborators
Animas Corporation
Responsible party
Sponsor
First posted
Jul 25, 2011
Start date
Jan 2011
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Nov 8, 2011

Study contacts

Ian W Gallen, MD FRCP
principal investigator · Buckinghamshire Healthcare NHS Trust

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion